Palantir closes up 21% on report of $44 million FDA contract

Products You May Like

A person wears a Palantir Technologies (PLTR) sweater outside the New York Stock Exchange (NYSE) on the day of their initial public offering (IPO) in Manhattan, New York City, U.S., September 30, 2020.

Andrew Kelly | Reuters

Shares of Palantir jumped more than 17% Monday after Bloomberg reported that the company won a three-year contract with the U.S. Food and Drug Administration.

The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.

Co-founded in 2003 by tech investors Peter Thiel and Joe Lonsdale, CEO Alex Karp and others, Palantir provides data analytics software and services to government agencies and large companies. But its government work makes up more than half of its revenue, bringing in $163 million in its latest quarter.

The company said in November recent contracts it received during the third quarter include a $91 million deal with the U.S. Army, a $36 million contract with the National Institutes of Health $36 million and a $300 million renewal with an aerospace customer.

Palantir stock has surged nearly 200% since it went public Sept. 30.

Subscribe to CNBC on YouTube.

News

Products You May Like

Articles You May Like

Fossil Gen 6 Hybrid Smartwatch to Launch on June 27 With Up to 2 Weeks of Battery Life
Fossil Gen 6 Hybrid Smartwatch Range With Inbuilt Alexa Support, SpO2 Tracking Launched in India
What Are Shadow IDs, and How Are They Crucial in 2022?
Electrode maker De Nora ‘not scared’ about volatility as it braves IPO
Intel warns Ohio factory could be delayed because Congress is dragging its feet on funding

Leave a Reply

Your email address will not be published.